Hemophilia A is the most common clotting disorder in humans. It affects one in five 41 thousand live-born children. Mutations in the X-chromosome linked F8 gene lead to the 42 deficiency of circulating factor VIII (FVIII). The defect is characterized by severe 43 bleeding. The standard therapy is to replace the deficient factor intravenously. The main 44 adverse event of the therapy is the development of anti-FVIII inhibitor antibodies that 45 impair coagulation and result in increased complications and risk of death. Several risk 46 factors have been described for the development of inhibitor antibodies, among them 47 age, type of FVIII administered, ethnicity, and variant alleles in immune response 48 genes. Epigenetic risks factors have not yet been explored. This work aimed to evaluate 49 2 the methylation statuses at thirteen CpG sites (5meCpG) in regulatory regions of the 50 IL1B, IL2, IL4, IL6, IL10, TNF, IFNG, CTLA4, CD28, and CST7 immune regulation 51 genes in hemophilia A affected males on replacement therapy who develop or do not 52 develop inhibitor antibodies. At each of the thirteen specific CpG sites, we observed one 53 of three possible statuses: hypermethylated, hypomethylated or intermediate 54 methylated. We found a statistically significant (p = 0.04) decrease in the methylation 55 level at one CpG site in the IL4 intron 1 (CpG-3) in the affected group of patients 56 presenting with anti-FVIII inhibitors as compared with the group of patients without 57 inhibitors. The differential 5meCpG-3 maps within a predicted enhancer region in IL4 58 intron 1 that overlaps DNase I hypersensitive chromatin region of the Th2 IL5, IL13, 59 and IL4 cytokine gene cluster and, therefore, permissive for gene expression. Six-bp 60 upstream of the differentially 5meCpG-3 is the rs2227282 cis expression quantitative 61 trait locus that influences the transcript levels of the PDLIM4, SLC22A4, SLC22A5, 62 RAD50, IL4, KIF3A, SEPT8 genes. We consider the IL4 (CpG-3) site a promising lead 63 epigenetic mark, the potential value of which must be appraised in a larger group of 64 patients. The methodology employed also allowed to evaluate the distribution of the IL6 65 rs35081782 insertion/deletion variant, associated with white blood cell count traits in 66 genome-wide association studies, and which showed no difference in distribution 67 between the groups of patients. 68 69 90 91
Introduction 70
Hemophilia A (MIM 306700) is the most severe and frequent blood clotting disorder in ® from Thermo Fisher Scientific, Waltham, MA, USA). The level of methylation at the 207 individual CpG sites was estimated as the normalized ratio of restriction enzyme-208 resistant amplimer after digestion as compared with the undigested product and 209 corrected by the proportion of resistant positive control amplimer, using the formula 210 previously reported (Alves da Silva et al., 2016; de Sa Machado Araujo et al., 2018) . 211 Target amplimers ranged 150 bp to 440 bp in length Control amplimers (resistant to 212 enzymatic digestion) were ten bp larger than the target amplimers (Supplemental Table   213 S3).
215
Characterization of Alleles 216 To the amplification products were added formamide (Hi-Di Formamide, Applied 217 Biosystems) and the GeneScan 500 molecular weight standard labeled with the 218 fluorochrome LIZ ™ (orange fluorescence) (Applied Biosystems). The amplification 219 products were separated by high resolution ((1 bp) capillary electrophoresis in the POP4 220 polymer using the ABI Prism ™ 310 Genetic Analyzer platform. The electrophoretic 221 profiles were analyzed using the GeneMapper ID 3.2 programs (Applied Biosystems).
223
Computational Cross-Referencing with 5meCpG Levels in Public Methylomes 224 We validated the levels of methylation at each specific CpG site in the target immune 225 regulatory/response genes observed in healthy individuals by computationally cross-226 referencing with data values from public genome-wide methylomes (bisulfite 227 sequencing -BS-Seq -experiments). We extracted data from the integrative analysis of 228 111 reference epigenomes (Roadmap Epigenomics et al., 2015) , available from the 229 University of California Santa Cruz (UCSC) Genome Browser (Kent et al., 2002; Raney 230 et al., 2014) . We selected BS-Seq experiments performed in DNA from whole-blood 231 (newborn and 100-year old donors), and the following blood-derived enriched cell 232 types: B-cell, T-cell, NK-cells, neutrophils, and macrophages. We also included the 233 methylomes from liver, lung, spleen, and thymus. Details of the methylome studies are 234 provided in Supplemental Table S4 Dataset A. The methylation values were extracted 235 using UCSC Genome Browser Data Integrator web tool (Hinrichs et al., 2016) and the 236 5meCpG site values were plotted using the ggplot2 graph data analysis (Wickham, 237 2016) in R-codes (R Core Team, 2018) .
239
Cross-Referencing with (Epi)genotype-Phenotype Associations 240 We lookup online public database about GWAS studies for evidence on the SNP and 241 CpG sites interrogated to identify possible phenotypes and disease-associated loci or 242 expression quantitative trait loci (eQTLs) and to assign chromatin states to the lead 243 variants and CpG sites. The strategy was as described previously for the differentially 244 methylated regions associated with genomic imprinting (Machado et al., 2014) 
Results

262
To select the target genes, we consider the immune regulatory mechanism of production 263 of anti-FVIII inhibitor antibodies. The exact mechanism of inhibitor production has not 264 yet been clarified, but it is proposed to initiate when antigen-presenting cells (APC) 265 endocytose the exogenous FVIII and degrade it into peptides. In turn, these peptides 266 bind to molecules of the major histocompatibility complex (HLA) class II, and Thus, our criteria to include an immune regulatory/ response gene included: (i) evidence 282 of regulation of the promoter region by DNA methylation (Table 1) Table 2 .
293
We determined the methylation status of thirteen individual CpG sites in ten target 294 genes ( Supplemental Table S3 ) using restriction enzyme methylation-sensitive PCR 295 triplex assays. For each CpG site, a specific MSRE-PCR assay was developed. We Initially, we interrogated all the thirteen specific CpG sites in a subset of samples (up to 303 ten cases and ten controls) and ten non-hemophilia A healthy subjects. At the particular 304 CpG sites, we consistently observed one of three possible methylation statuses: Figure S10 . The distribution of 312 methylation levels was similar among the three groups ( Figure S11 ). In the discovery 313 set limited to ten individuals per group, no significant statistical difference was found 314 for any of the targets between the three groups of subjects (p>0.05). Based on the 315 observed profiles and the extent of the interindividual variation in methylation levels, 316 we narrowed down the analysis to five specific CpG sites to profile the full set of 317 twenty patients with inhibitors, twenty patients without inhibitors and twenty non- (Figure 3 ), we observed a discrete, yet statistically significant decrease in the 324 methylation levels at the IL4 (CpG-3) between the affected patients presenting with 325 anti-FVIII inhibitors as compared with those without (95% CI [-1.009e-01-5.149e-5]),
326
Wilcoxon Rank Sum Test with continuity correction p = 0.04; Figure 4 and 327 Supplemental Table S5 ). We also noted that all the evaluated CpG sites at the target 328 genes showed concordant levels of methylation reported in several methylome studies 329 from diverse biological samples withdrawn from healthy subjects (Supplemental Table   330 S4 Dataset B).
332
Within the IL6 amplimer, there is a two-base pair deletion, referring to the SNP 333 rs35081782 (NC_000007.13:g.22765338_22765339CT [3] ). Although the deletion had a 334 lower frequency in the group of hemophilia A with inhibitors (15%), no significant 335 difference was found in the distribution of the variant between the three groups here 336 evaluated (Table S6 ). Cross-referencing with the PhenoScanner GWAS public database, 337 we found that in one study (Astle et al., 2016) the rs35081782 indel variant has been 338 associated at genome-wide scores with white blood cell count traits linked to common 339 complex diseases ( We also noted that most of the 5meCpG sites (IL10, IFNG, CST7, IL4, and TNF) 348 exhibited gametic asymmetry in that the oocyte´s DNA was hypomethylated and the 349 sperm´s DNA was hypermethylated (Table S4 Dataset 
365
We also noted the occurrence of the SNP rs2227282 (NC_000005.9:g.132013179C>G) CpG islands at the intron 1 being systematically hypermethylated.
414
Our analysis indicates that only the IL4 (CpG-3) site exhibited statistical differences at 415 the methylation statuses between the group of hemophilia A patients who are positive 416 for inhibitors and the group of patients who are negative for the anti-FVIII antibodies. 417 We envision the IL4 (CpG-3) site as a promising lead epigenetic mark, whose potential 418 value must be appraised in a more significant number of patients. IL-4 has 419 immunomodulatory activity, being one of the main effectors in the polarization for a 420 Th2 response. As pointed earlier, the IL4 gene is located within the Th2 immune 421 response regulatory IL5, IL13, and IL4 cytokine locus. The Th2 region has several sites 422 for binding of the chromatin remodeling transcription factor GATA3, which stimulates 527 We thank all participants and their guardians for the superb willingness to contribute to 528 this study. gametes (oocyte and sperm) and somatic tissues (blood, spleen, lung, thymus and liver) . 746 The methylation levels are represented on a scale from 0 to 1 (hypomethylated to 747 hypermethylated). Note the overall hypomethylation statuses of the CpGs spanning the 748 CST7 gene in DNA from oocytes in contrast to the hypermethylated statuses in sperm 749 and somatic tissues. Therefore, in the CST7 gene region, there is asymmetrical 750 methylation in gametes (hypomethylation in oocytes and hypermethylation in 751 spermatozoa). Screenshot prepared using public and custom hubs available from the 752 UCSC Genome Browser (Kent et al., 2002; Raney et al., 2014) Table S6 . Genotypes of the IL6 rs35081782 indel variant in the studied groups of 850 subjects 851 852 Table S7 . Genome-wide significance of associations between the IL4 rs2227282, IL6 853 rs35081782 and human diseases and traits from cross-referencing with genotype-854 phenotype genome-wide associations studies (GWAS) from PhenoScanner (Dataset A); 855 HaploReg lookup of regulatory chromatin states at the lead variant IL4 rs2227282 856 (Dataset B); associated traits from HaploReg (Dataset C), and predicted network of 857 protein-protein interactions from STRING database (Dataset D) 858 
